Navigation Links
Heart Failure: Targeting the right patients for CRT-D
Date:5/22/2011

Patients with dyssynchronous yet viable ventricles are most likely to benefit from cardiac resynchronization therapy combined with defibrillation, concludes the latest analysis of the MADIT CRT trial. The CRT-MADIT-CRT trial - presented at the Heart Failure Congress 2011, organized by the Heart Failure Association of the European Society of Cardiology (ESC) in Late Breaking Session 1 - showed that CRT produced improvements in both synchrony and contractile function, and that the extent of this benefit relates to subsequent outcomes.

The Multicentre Automatic Defibrillator Implantation Trial-CRT (MADIT-CRT) set out to determine whether patients with mild heart failure (NYHA class I or II) would do better if they got implanted with a CRT-D device (which combines cardiac resynchronization therapy with defibrillation), than if they only received the traditional ICD defibrillation. In earlier studies CRT-D devices had been approved for use in patients with severe heart failure (NYHA class III/IV).

In the MADIT-CRT study, funded by Boston Scientific, 1820 patients with Class I and II heart failure, wide QRS and left ventricular dysfunction were randomized 3:2 to receive CRT-D (n=1089) or ICD alone (n=731). Results, presented at the 2009 ESC Annual Conference in Barcelona after a follow period averaging 2.4 years, demonstrated a greater than 40% reduction in the primary endpoint of death or heart failure in patients receiving CRT-D. However, in virtually all studies of CRT-D approximately 30% of patients do not respond to therapy.

In the current study, Dr Scott D Solomon (Brigham and Women's Hospital, Boston, MA) and colleagues set out to investigate whether the degree of synchrony the extent to which the walls of the left ventricle contract in unison might influence the likelihood of patients responding to CRT-D. "It's important to target patients in whom CRT-D works well because the technology is quite expensive," explained Solomon.

In this latest analysis of MADIT-CRT, investigators analyzed echocardiograms from 1077 patients enrolled in MADIT-CRT (CRT-D n=66; ICD, n=416) who had echocardiographic images of sufficient quality to allow analysis of synchrony and contractile function. Researchers were blinded to the randomization and study outcomes.

Results showed that patients with mild to moderate dyssynchrony at baseline (defined as a time-to peak transverse strain SD of 142-230 ms) and greater baseline contractile function (longitudinal strain < -8.7%) improved to a greater extent when randomised to the CRT-D group than the ICD only group.

The study showed that over a year each 10 ms decrease in LV dyssynchrony was associated with a 3% reduction in the primary outcome of death or heart failure, and each 5 point absolute increase in LV strain was associated with a 75% reduction in the primary outcome.

"These results suggest that the patients who are most likely to benefit from CRT-D are those with at least some dyssynchrony who have relatively preserved contractile function," said Solomon, adding that the observation that improvements in synchrony and contractile function were associated with reduced death and heart failure events, suggests that the benefits delivered by CRT relate to improvements in these factors. "Future studies will continue to try to identify the patients who are most likely to benefit from this expensive but highly effective therapy," he said.


'/>"/>

Contact: Jacqueline Partarrieu
press@escardio.org
33-492-947-756
European Society of Cardiology
Source:Eurekalert

Related biology news :

1. Dark chocolate: Half a bar per week to keep at bay the risk of heart attack
2. NIH awards Clemson bioengineer $1.5 million to improve durability of tissue heart valves
3. Researchers study how pistachios may improve heart health
4. Argonne scientists peer into heart of compound that may detect chemical, biological weapons
5. LIAI launches new division to look at novel approaches to heart disease and inflammation
6. Study provides insight on a common heart rhythm disorder
7. Embryonic heart exhibits impressive regenerative capacity
8. Repair in the developing heart
9. Drug-embedded microparticles bolster heart function in animal studies
10. Heart valves that grow with the patient
11. Research uncovers new steps on pathway to enlarged heart
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... research undertaken by Fit Small Business has revealed ... simply asked which office technology had they not used in ... Insights on what will be key features in ... industry leaders including Penelope Trunk , Martin Lindstrom ... Some of these findings included; ...
(Date:1/6/2017)... , Jan. 5, 2017  SomaLogic announced today ... Life Alliance" established by iCarbonX, the ... build a "Global Digital Health Ecosystem that can ... combination of individual,s biological, behavioral and psychological data, ... between the companies, SomaLogic will provide proteomics data ...
(Date:12/22/2016)... , Dec. 20, 2016  As part of its longstanding ... leading personal genetics company, recently released its latest children,s book, ... The book focuses on the topics of inheritance and variation ... Standards (NGSS) taught in elementary school classrooms in the US. ... series by illustrator Ariana Killoran , whose previous book ...
Breaking Biology News(10 mins):
(Date:1/18/2017)... According to a new market research report "In situ Hybridization Market by Technique ... Diagnostic Laboratories, Academic and Research Institutions) - Global Forecast to 2021" published by ... USD 557.1 Million in 2016, growing at a CAGR of 5.8%. ... ... MarketsandMarkets Logo ...
(Date:1/18/2017)... Jan. 18, 2017 Applied BioMath ( ... to drug research and development, today announced that ... and CEO of Applied BioMath, will present at ... Modeling (BAGIM) Meeting on Thursday January 19, 2017 ... , MA.   Dr. Burke,s talk "Quantitative Modeling ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... Ops Executives 2017 in its continued commitment to the advancement of the clinical ... discuss current issues related to clinical trial planning and management. , As ...
(Date:1/18/2017)... , ... January 18, 2017 , ... ... and more E&L expertise. Within Albany Molecular Research, Inc. (AMRI), the scientific staff ... past year and is planned for further growth in 2017. Extractable & Leachable ...
Breaking Biology Technology: